NCT04448717View on ClinicalTrials.gov

COVID-19: Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children

CompletedOBSERVATIONAL
Enrollment

4,250

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

July 20, 2022

Study Completion Date

July 20, 2022

Conditions
SARS-CoV 2COVID-19
Interventions
DIAGNOSTIC_TEST

COVID-19 Antibody testing

COVID-19 Antibody testing in venous blood and/or saliva samples.

Trial Locations (1)

8001

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich

All Listed Sponsors
collaborator

Swiss School of Public Health (SSPH+)

OTHER

lead

University of Zurich

OTHER

NCT04448717 - COVID-19: Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children | Biotech Hunter | Biotech Hunter